TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 33317481

Group type: EXPERIMENTAL
Intervention: Mindfulness-based cognitive therapy
Number of subjects: 187

Group type: EXPERIMENTAL
Intervention: Health qigong-based cognitive therapy
Number of subjects: 187

Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 187
Study: 37393402

Group type: EXPERIMENTAL
Intervention: Bepirovirsen 300 mg (with 300 mg loading dose) for 24 weeks
Number of subjects: 457

Group type: EXPERIMENTAL
Intervention: Bepirovirsen 300 mg (with 300 mg loading dose) for 12 weeks then bepirovirsen 150 mg for 12 weeks
Number of subjects: 457

Group type: EXPERIMENTAL
Intervention: Bepirovirsen 300 mg (with 300 mg loading dose) for 12 weeks then placebo for 12 weeks
Number of subjects: 457

Group type: EXPERIMENTAL
Intervention: Placebo for 12 weeks (with placebo loading dose) then bepirovirsen 300 mg without loading dose for 12 weeks
Number of subjects: 457
Study: 34429312

Group type: EXPERIMENTAL
Intervention: QLBA (anterior quadratus lumborum block at the lateral supra-arcuate ligament)
Number of subjects: 100

Group type: COMPARATOR
Intervention: QLB2 (posterior quadratus lumborum block)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: QLBA
Number of subjects: 100

Group type: COMPARATOR
Intervention: QLB2
Number of subjects: 100
Study: 32957397

Group type: EXPERIMENTAL
Intervention: Preoperative nursing visit (experiential group)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Control group (no preoperative nursing visit)
Number of subjects: 200
Study: 86099028

Group type: EXPERIMENTAL
Intervention: D-penicillamine and prednisone (low-dose combination therapy)
Number of subjects: 25

Group type: COMPARATOR
Intervention: D-penicillamine alone
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 32091466

Group type: EXPERIMENTAL
Intervention: Daily nonlinear periodization (NLP)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Flexible daily nonlinear periodization (FNLP)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Nonperiodization (NP)
Number of subjects: 58
Study: 33566465

Group type: EXPERIMENTAL
Intervention: Enoxaparin started less than 24 hours after insertion of central venous catheter, adjusted to anti-Xa level of 0.2–0.5 international units/mL
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Enoxaparin
Number of subjects: 51
Study: 35525503

Group type: EXPERIMENTAL
Intervention: Holmium Laser En‐bloc Resection of Bladder Tumors (HoLERBT)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Transurethral Resection of Bladder Tumor (TURBT)
Number of subjects: 8
Study: 36286503

Group type: EXPERIMENTAL
Intervention: Physical training intervention with music
Number of subjects: 0
Study: 34293156

Group type: EXPERIMENTAL
Intervention: 8-week advocacy program
Number of subjects: 50

Group type: COMPARATOR
Intervention: Physical activity (PA) comparison intervention
Number of subjects: 50
Study: 32169923

Group type: EXPERIMENTAL
Intervention: Standardised self-management kits
Number of subjects: 308

Group type: COMPARATOR
Intervention: Usual treatment (Control)
Number of subjects: 308

Group type: COMPARATOR
Intervention: Standardised self-management kits and Usual treatment (Control)
Number of subjects: 308
Study: 34348522

Group type: EXPERIMENTAL
Intervention: Walking on a treadmill during the post-test phase
Number of subjects: 36

Group type: COMPARATOR
Intervention: Sitting during the post-test phase
Number of subjects: 36
Study: 32960464

Group type: EXPERIMENTAL
Intervention: G‐MEDSS with usual care HMR
Number of subjects: 201

Group type: COMPARATOR
Intervention: Usual care HMR alone
Number of subjects: 201
Study: 32574657

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT) intervention (four sessions)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Waitlisted control group
Number of subjects: 60
Study: 35183180

Group type: EXPERIMENTAL
Intervention: Mindfulness-based intervention (MAP-I)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cognitive Behavioral Therapy for Insomnia (CBT-I)
Number of subjects: 0
Study: 32909309

Group type: EXPERIMENTAL
Intervention: On-road driving rehabilitation program (immediate intervention)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Wait-list group (6 weeks delay)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Overall participants (both groups)
Number of subjects: 8
Study: 32557974

Group type: EXPERIMENTAL
Intervention: HDM sublingual immunotherapy (SLIT)
Number of subjects: 112

Group type: COMPARATOR
Intervention: Pharmacotherapy alone
Number of subjects: 112
Study: 34464386

Group type: EXPERIMENTAL
Intervention: Online teaching after COVID-19 lockdown
Number of subjects: 79
Study: 33444192

Group type: EXPERIMENTAL
Intervention: 2.5 min passive work breaks including rest
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: 2.5 min active work breaks including mobility and stretching exercises
Number of subjects: 21

Group type: COMPARATOR
Intervention: No work breaks
Number of subjects: 21
Study: 35173164

Group type: EXPERIMENTAL
Intervention: Adjuvant trastuzumab emtansine (T-DM1)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Adjuvant paclitaxel with trastuzumab (TH)
Number of subjects: 100
Study: 33346013

Group type: EXPERIMENTAL
Intervention: Narrative Review (NR)
Number of subjects: 111

Group type: COMPARATOR
Intervention: Systematic Review (SR)
Number of subjects: 111
Study: 33970719

Group type: EXPERIMENTAL
Intervention: Modified lottery for research funding allocation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Peer review system for research funding allocation
Number of subjects: 0
Study: 34245960

Group type: EXPERIMENTAL
Intervention: Complete wound drain removal 3 weeks after surgery
Number of subjects: 99

Group type: COMPARATOR
Intervention: Progressive drain removal
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: ILND
Number of subjects: 99
Study: 33208575

Group type: EXPERIMENTAL
Intervention: Scotchbond Multi‐purpose with silane contamination after-etching
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Scotchbond Multi‐purpose with silane contamination after-priming
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Optibond FL with silane contamination after-etching
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Optibond FL with silane contamination after-priming
Number of subjects: 160

Group type: COMPARATOR
Intervention: Scotchbond Multi‐purpose without silane contamination
Number of subjects: 160

Group type: COMPARATOR
Intervention: Optibond FL without silane contamination
Number of subjects: 160
Study: 34379802

Group type: EXPERIMENTAL
Intervention: Intralymphatic immunotherapy (ILIT) with up-dosage of 1000-3000-10,000 SQ-U (5000 + 5000 with 30 minutes apart)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Intralymphatic immunotherapy (ILIT) with modified up-dosing schedule of 1000-3000-3000 SQ-U
Number of subjects: 68

Group type: COMPARATOR
Intervention: Intralymphatic immunotherapy (ILIT)
Number of subjects: 68
Study: 34022336

Group type: EXPERIMENTAL
Intervention: Positive-test participants
Number of subjects: 840

Group type: COMPARATOR
Intervention: Negative-test participants
Number of subjects: 840
Study: 32036610

Group type: EXPERIMENTAL
Intervention: Mixed HDF
Number of subjects: 120

Group type: COMPARATOR
Intervention: Post-HDF
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Mixed HDF vs Post-HDF
Number of subjects: 120
Study: 35749343

Group type: EXPERIMENTAL
Intervention: Power to Quit (PTQ) program
Number of subjects: 315
Study: 33832089

Group type: EXPERIMENTAL
Intervention: COPD medical treatment + KT (Group 1)
Number of subjects: 0

Group type: COMPARATOR
Intervention: COPD medical treatment alone (Group 2)
Number of subjects: 0
Study: 32376313

Group type: EXPERIMENTAL
Intervention: Combination of an intrauterine device (IUD) with a Foley catheter after hysteroscopic adhesiolysis
Number of subjects: 118

Group type: COMPARATOR
Intervention: Balloon uterine stent insertion after hysteroscopic adhesiolysis
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Both groups (IUD + Foley catheter and balloon uterine stent)
Number of subjects: 118
Study: 34275789

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine combined with citrate sufentanil
Number of subjects: 70

Group type: COMPARATOR
Intervention: Dexmedetomidine
Number of subjects: 70
Study: 34955257

Group type: EXPERIMENTAL
Intervention: Low compound probiotics (0.12 g per head per day)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: High compound probiotics (1.2 g per head per day)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Compound probiotics (both low and high)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control group (milk replacer with no compound probiotics)
Number of subjects: 48
Study: 32686755

Group type: EXPERIMENTAL
Intervention: Embrace Nest Infant Warmer
Number of subjects: 120

Group type: COMPARATOR
Intervention: Cloth Wrap
Number of subjects: 120
Study: 32910710

Group type: EXPERIMENTAL
Intervention: Continuous nivolumab (3 mg/kg every 2 weeks)
Number of subjects: 252

Group type: COMPARATOR
Intervention: 1-year fixed-duration nivolumab
Number of subjects: 252

Group type: EXPERIMENTAL
Intervention: Continuous nivolumab
Number of subjects: 252
Study: 36503480

Group type: EXPERIMENTAL
Intervention: Scheduled lung recruitment maneuvers (LRMs) at 12-hour intervals and when clinically indicated
Number of subjects: 30

Group type: COMPARATOR
Intervention: Only when clinically indicated (control)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Scheduled LRMs
Number of subjects: 30
Study: 36269184

Group type: EXPERIMENTAL
Intervention: Repeated low-level red light (RLRL) therapy
Number of subjects: 62

Group type: COMPARATOR
Intervention: 0.01% atropine eye drops (LDA)
Number of subjects: 62
Study: 32357329

Group type: EXPERIMENTAL
Intervention: Anterior cervical discectomy and fusion
Number of subjects: 68

Group type: COMPARATOR
Intervention: Posterior laminectomy with or without fusion
Number of subjects: 68
Study: 34969176

Group type: EXPERIMENTAL
Intervention: Mindfulness exercises performed in the classroom over the course of 7 weeks
Number of subjects: 125
Study: 32658528

Group type: EXPERIMENTAL
Intervention: Prolonged control deprivation
Number of subjects: 487
Study: 631563192

Group type: EXPERIMENTAL
Intervention: Mean carotid intima-media thickness (cIMT)
Number of subjects: 11547

Group type: EXPERIMENTAL
Intervention: Mean carotid intima-media thickness (cIMT) categorized in quartiles
Number of subjects: 11547

Group type: EXPERIMENTAL
Intervention: Higher mean arterial pressure (>=109.3 mm Hg)
Number of subjects: 11547

Group type: EXPERIMENTAL
Intervention: Higher diastolic blood pressure levels (>=90.7 mm Hg)
Number of subjects: 11547
Study: 33947856

Group type: EXPERIMENTAL
Intervention: PfSPZ vaccine (1.1 × 10^5 aseptic, purified, cryopreserved PfSPZ of the PfNF54 strain) with 10 mg/kg chloroquine base
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo (normal saline) with 10 mg/kg chloroquine base
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: PfSPZ vaccine
Number of subjects: 18
Study: 33168081

Group type: EXPERIMENTAL
Intervention: Closed incision negative pressure wound therapy (ciNPWT) for 7 days
Number of subjects: 222

Group type: COMPARATOR
Intervention: Gauze dressing (control)
Number of subjects: 222
Study: 34540636

Group type: EXPERIMENTAL
Intervention: Epidural dexmedetomidine
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Epidural ropivacaine
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control (oral medication: cyproterone compound tablets 50 mg BD and diazepam tablets 2 mg TDS for a week)
Number of subjects: 45
Study: 35872074

Group type: EXPERIMENTAL
Intervention: Oral tacrolimus (5 mg)
Number of subjects: 4874

Group type: COMPARATOR
Intervention: Oral placebo
Number of subjects: 4874
Study: 34491350

Group type: EXPERIMENTAL
Intervention: Financial incentives group
Number of subjects: 344

Group type: EXPERIMENTAL
Intervention: Environmental strategies group
Number of subjects: 344

Group type: EXPERIMENTAL
Intervention: Combined financial incentives and environmental strategies group
Number of subjects: 344

Group type: COMPARATOR
Intervention: Usual care group (control)
Number of subjects: 344
Study: 35692440

Group type: EXPERIMENTAL
Intervention: CR+SIT LESS (intervention)
Number of subjects: 212

Group type: COMPARATOR
Intervention: CR (control)
Number of subjects: 212
Study: 32768992

Group type: EXPERIMENTAL
Intervention: nabiximols
Number of subjects: 128

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 128
Study: 36137137

Group type: EXPERIMENTAL
Intervention: Plyometric exercises (PLYO)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Weightlifting derivatives (WL)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 45
Study: 32279141

Group type: EXPERIMENTAL
Intervention: Chinese Prostate Cancer Consortium Risk Calculator (CPCC‐RC)
Number of subjects: 617

Group type: EXPERIMENTAL
Intervention: Asian adapted Rotterdam European Randomized Study of Screening for Prostate Cancer Risk Calculator 3 (A‐ERSPC‐RC3)
Number of subjects: 617

Group type: EXPERIMENTAL
Intervention: Decision curve analysis for CPCC‐RC
Number of subjects: 617

Group type: EXPERIMENTAL
Intervention: Decision curve analysis for A‐ERSPC‐RC3
Number of subjects: 617
Study: 35279214

Group type: EXPERIMENTAL
Intervention: D‐SOX group (intraperitoneal infusion of docetaxel 30 mg/m2 on d1 and d8, intravenous oxaliplatin 100 mg/m2 on d1, and oral administration of S‐1 on d1‐d14)
Number of subjects: 78

Group type: COMPARATOR
Intervention: DOS group (intravenous docetaxel 60 mg/m2 on d1, intravenous oxaliplatin 100 mg/m2 on d1, and oral administration of S‐1 on d1‐d14)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: D‐SOX group
Number of subjects: 78

Group type: COMPARATOR
Intervention: DOS group
Number of subjects: 78
Study: 33761207

Group type: EXPERIMENTAL
Intervention: 200 mg abrocitinib
Number of subjects: 838

Group type: EXPERIMENTAL
Intervention: 100 mg abrocitinib
Number of subjects: 838

Group type: EXPERIMENTAL
Intervention: Dupilumab
Number of subjects: 838

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 838
Study: 36134643

Group type: EXPERIMENTAL
Intervention: VLBW/VP group
Number of subjects: 50

Group type: COMPARATOR
Intervention: ADHD group
Number of subjects: 50
Study: 33843647

Group type: EXPERIMENTAL
Intervention: Standardized questionnaire assessment of health status
Number of subjects: 355

Group type: EXPERIMENTAL
Intervention: Recommendations for improving adaptation to a multinational environment
Number of subjects: 355
Study: 32024651

Group type: EXPERIMENTAL
Intervention: PGA cut-off of 1.5 cm
Number of subjects: 2600

Group type: EXPERIMENTAL
Intervention: PGA cut-off of 2.0 cm
Number of subjects: 2600

Group type: EXPERIMENTAL
Intervention: PGA thresholds (Boolean, 1.5, 2.0, 2.5, 3.0, BooleanX)
Number of subjects: 2600
Study: 34425586

Group type: EXPERIMENTAL
Intervention: Cention N (CN)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Beautifil-bulk Restorative (BB)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Activa Bioactive Restorative (AV)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Filtek Z350 (FZ)
Number of subjects: 40
Study: 32247603

Group type: EXPERIMENTAL
Intervention: Weekly gemcitabine (1000 mg/m2 on days 1 and 8 of a 21 day cycle) plus pazopanib (800 mg QD)
Number of subjects: 148

Group type: COMPARATOR
Intervention: Weekly gemcitabine (1000 mg/m2 on days 1 and 8 of a 21 day cycle) alone
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Weekly gemcitabine plus pazopanib
Number of subjects: 148

Group type: COMPARATOR
Intervention: Weekly gemcitabine alone
Number of subjects: 148
Study: 36504640

Group type: EXPERIMENTAL
Intervention: Direct mechanical thrombectomy (MT)
Number of subjects: 290

Group type: COMPARATOR
Intervention: Bridging therapy
Number of subjects: 290
Study: 33302879

Group type: EXPERIMENTAL
Intervention: exercise intervention + protein placebo + omega-3 fatty acids placebo
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: protein + omega-3 fatty acids placebo
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: exercise intervention + protein + omega-3 fatty acids placebo
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: exercise intervention + protein + omega-3 fatty acids
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: protein placebo + omega-3 fatty acids placebo
Number of subjects: 180
Study: 35772594

Group type: EXPERIMENTAL
Intervention: Clinical and laboratory variables (age, pulse, serum urea, serum sodium, white blood cell count)
Number of subjects: 2645

Group type: EXPERIMENTAL
Intervention: Dynamic nomogram based on clinical and laboratory variables
Number of subjects: 2645

Group type: EXPERIMENTAL
Intervention: Laparoscopic approach
Number of subjects: 2645

Group type: EXPERIMENTAL
Intervention: Presence of peritoneal soiling (PS)
Number of subjects: 2645
Study: 32005175

Group type: EXPERIMENTAL
Intervention: Continuous intrajejunal Levodopa Infusion (CLI)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Deep Brain Stimulation (DBS)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Both CLI and DBS
Number of subjects: 66
Study: 35403244

Group type: EXPERIMENTAL
Intervention: SMOF lipid emulsion (SMOF‐LE)
Number of subjects: 528

Group type: COMPARATOR
Intervention: Non-SMOF lipid emulsion (non–SMOF‐LE)
Number of subjects: 528
Study: 32345839

Group type: EXPERIMENTAL
Intervention: Obese (BMI ≥ 30)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Normal weight (BMI ≤ 25)
Number of subjects: 67
Study: 34762731

Group type: EXPERIMENTAL
Intervention: Peanut skin diet and SE inoculation (PSSE)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Control diet with SE inoculation (CONSE)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Control diet without SE inoculation (CON)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Peanut skin diet without SE inoculation (PS)
Number of subjects: 160
Study: 32080823

Group type: EXPERIMENTAL
Intervention: Alirocumab 75 mg
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Alirocumab 150 mg
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Alirocumab 300 mg
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study: 35311317

Group type: EXPERIMENTAL
Intervention: Strategic deception training
Number of subjects: 80

Group type: COMPARATOR
Intervention: Conservation training control
Number of subjects: 80
Study: 34414985

Group type: EXPERIMENTAL
Intervention: Passive stretching
Number of subjects: 3

Group type: COMPARATOR
Intervention: Handling for active or active-assist movement
Number of subjects: 3

Group type: COMPARATOR
Intervention: Thermotherapy
Number of subjects: 3
Study: 35027405

Group type: EXPERIMENTAL
Intervention: Tofacitinib
Number of subjects: 102263
Study: 34118188

Group type: EXPERIMENTAL
Intervention: Dextromethorphan derivatives
Number of subjects: 2

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2
Study: 33793556

Group type: EXPERIMENTAL
Intervention: Rapid immunoglobulin M (IgM)/immunoglobulin G (IgG) test kit
Number of subjects: 844
Study: 32289292

Group type: EXPERIMENTAL
Intervention: 0 medications
Number of subjects: 1400

Group type: EXPERIMENTAL
Intervention: 1 medication
Number of subjects: 1400

Group type: EXPERIMENTAL
Intervention: 2 medications
Number of subjects: 1400

Group type: EXPERIMENTAL
Intervention: 3 medications
Number of subjects: 1400

Group type: EXPERIMENTAL
Intervention: 4 medications
Number of subjects: 1400
Study: 36064592

Group type: EXPERIMENTAL
Intervention: Guselkumab every 4 weeks (Q4W)
Number of subjects: 405

Group type: EXPERIMENTAL
Intervention: Guselkumab at week 0, week 4, then every 8 weeks (Q8W)
Number of subjects: 405

Group type: COMPARATOR
Intervention: Placebo with crossover to guselkumab at week 24, week 28, then Q8W
Number of subjects: 405

Group type: EXPERIMENTAL
Intervention: Guselkumab (all dosing regimens)
Number of subjects: 405
Study: 32776235

Group type: EXPERIMENTAL
Intervention: Drug-coated balloon catheter (DCB) treatment for ISR
Number of subjects: 396

Group type: COMPARATOR
Intervention: Plain balloon angioplasty
Number of subjects: 396

Group type: EXPERIMENTAL
Intervention: DCB treatment for ISR
Number of subjects: 396
Study: 34657160

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy for Insomnia (CBT-I) - Healthy Sleep (HS); 4 sessions over 8 weeks
Number of subjects: 175

Group type: COMPARATOR
Intervention: HF self-management education - Healthy Hearts (HH); attention control
Number of subjects: 175
Study: 32521566

Group type: EXPERIMENTAL
Intervention: Dupilumab treatment
Number of subjects: 46
Study: 35999068

Group type: EXPERIMENTAL
Intervention: PAD without diabetes
Number of subjects: 48

Group type: COMPARATOR
Intervention: PAD with diabetes
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: PAD with and without diabetes
Number of subjects: 48
Study: 34382063

Group type: EXPERIMENTAL
Intervention: High MAP group (average MAP ≥ 70 mmHg)
Number of subjects: 192

Group type: COMPARATOR
Intervention: Low MAP group (average MAP < 70 mmHg)
Number of subjects: 192
Study: 32478913

Group type: EXPERIMENTAL
Intervention: Blood donation
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 36
Study: 36235860

Group type: EXPERIMENTAL
Intervention: Low-absorbable geraniol food supplement (LAGS) once daily for four weeks
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study: 33710294

Group type: EXPERIMENTAL
Intervention: Nurse practitioner-led orthogeriatric care program (NPOCP)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 300
Study: 35333199

Group type: EXPERIMENTAL
Intervention: Hyaluronic acid filler Restylane Refyne (HARR, n = 20)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Saline (n = 6)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Needle injection
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Cannula injection
Number of subjects: 26
Study: 32095992

Group type: EXPERIMENTAL
Intervention: Tegaderm
Number of subjects: 151

Group type: COMPARATOR
Intervention: EyeGard
Number of subjects: 151
Study: 35361115

Group type: EXPERIMENTAL
Intervention: Winged and ported catheters (Vasofix® Safety, B. Braun)
Number of subjects: 2304

Group type: COMPARATOR
Intervention: Non-winged, non-ported catheters (Introcan® Safety, B. Braun)
Number of subjects: 2304

Group type: EXPERIMENTAL
Intervention: Needle reinsertions during catheterization
Number of subjects: 2304
Study: 32734288

Group type: EXPERIMENTAL
Intervention: Patient-initiated DMARD self-monitoring service
Number of subjects: 100

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Combined costs and effectiveness measures of ESR and quality of life (Short Form-12v1)
Number of subjects: 100